EA010371B1 - Тканевые протективные цитокины для защиты, восстановления и стимуляции реактивных клеток, тканей и органов - Google Patents

Info

Publication number

EA010371B1

EA010371B1 EA200500149A EA200500149A EA010371B1 EA 010371 B1 EA010371 B1 EA 010371B1 EA 200500149 A EA200500149 A EA 200500149A EA 200500149 A EA200500149 A EA 200500149A EA 010371 B1 EA010371 B1 EA 010371B1

Authority

EA

Eurasian Patent Office

Prior art keywords

cells

erythropoietin

tissue protective

protective cytokine

alpha

Prior art date

2002-07-03

Links

• Espacenet
• Global Dossier
• Discuss

• 102000004127 Cytokines Human genes 0.000 title claims abstract description 300
• 108090000695 Cytokines Proteins 0.000 title claims abstract description 299
• 230000002669 organ and tissue protective effect Effects 0.000 title claims abstract description 286
• 210000000056 organ Anatomy 0.000 title claims abstract description 119
• 238000000034 method Methods 0.000 claims abstract description 168
• 206010061218 Inflammation Diseases 0.000 claims abstract description 56
• 230000004054 inflammatory process Effects 0.000 claims abstract description 56
• 241000124008 Mammalia Species 0.000 claims abstract description 54
• 230000002519 immonomodulatory effect Effects 0.000 claims abstract description 42
• 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 8
• OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 405
• 108090000394 Erythropoietin Proteins 0.000 claims description 393
• 102000003951 Erythropoietin Human genes 0.000 claims description 388
• 229940105423 erythropoietin Drugs 0.000 claims description 388
• 210000004027 cell Anatomy 0.000 claims description 254
• 210000001519 tissue Anatomy 0.000 claims description 126
• 239000008194 pharmaceutical composition Substances 0.000 claims description 89
• 238000012986 modification Methods 0.000 claims description 63
• 230000000694 effects Effects 0.000 claims description 62
• 230000004048 modification Effects 0.000 claims description 62
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 58
• 230000004888 barrier function Effects 0.000 claims description 51
• 108010027485 asialoerythropoietin Proteins 0.000 claims description 50
• 239000003795 chemical substances by application Substances 0.000 claims description 50
• 108090000623 proteins and genes Proteins 0.000 claims description 43
• 238000011282 treatment Methods 0.000 claims description 43
• 230000006378 damage Effects 0.000 claims description 42
• 238000012360 testing method Methods 0.000 claims description 42
• 201000010099 disease Diseases 0.000 claims description 41
• 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 40
• 125000003277 amino group Chemical group 0.000 claims description 39
• 238000006243 chemical reaction Methods 0.000 claims description 39
• 210000002889 endothelial cell Anatomy 0.000 claims description 34
• -1 mycofen Chemical compound 0.000 claims description 33
• 150000001720 carbohydrates Chemical class 0.000 claims description 32
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 32
• 239000003814 drug Substances 0.000 claims description 30
• 235000014633 carbohydrates Nutrition 0.000 claims description 29
• 102000004169 proteins and genes Human genes 0.000 claims description 29
• 235000018102 proteins Nutrition 0.000 claims description 28
• 230000008499 blood brain barrier function Effects 0.000 claims description 23
• 210000001218 blood-brain barrier Anatomy 0.000 claims description 23
• 239000003937 drug carrier Substances 0.000 claims description 22
• 230000002829 reductive effect Effects 0.000 claims description 22
• OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical group O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 claims description 20
• 125000005629 sialic acid group Chemical group 0.000 claims description 20
• 238000004519 manufacturing process Methods 0.000 claims description 19
• 210000002216 heart Anatomy 0.000 claims description 18
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 17
• 239000004472 Lysine Substances 0.000 claims description 17
• 239000002260 anti-inflammatory agent Substances 0.000 claims description 17
• 229940121363 anti-inflammatory agent Drugs 0.000 claims description 16
• 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 16
• 239000007924 injection Substances 0.000 claims description 16
• 238000002347 injection Methods 0.000 claims description 16
• 208000028867 ischemia Diseases 0.000 claims description 16
• 210000004072 lung Anatomy 0.000 claims description 15
• 210000001550 testis Anatomy 0.000 claims description 15
• 229940079593 drug Drugs 0.000 claims description 14
• 108010057085 cytokine receptors Proteins 0.000 claims description 13
• 102000003675 cytokine receptors Human genes 0.000 claims description 13
• 210000003734 kidney Anatomy 0.000 claims description 13
• 210000002569 neuron Anatomy 0.000 claims description 13
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 13
• 210000001185 bone marrow Anatomy 0.000 claims description 12
• 230000003920 cognitive function Effects 0.000 claims description 12
• 230000028993 immune response Effects 0.000 claims description 12
• 210000001672 ovary Anatomy 0.000 claims description 12
• 239000003246 corticosteroid Substances 0.000 claims description 11
• 230000001965 increasing effect Effects 0.000 claims description 11
• 210000000813 small intestine Anatomy 0.000 claims description 11
• PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 10
• 108010036949 Cyclosporine Proteins 0.000 claims description 10
• QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical compound CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 claims description 10
• 210000004404 adrenal cortex Anatomy 0.000 claims description 10
• 210000001943 adrenal medulla Anatomy 0.000 claims description 10
• 208000029028 brain injury Diseases 0.000 claims description 10
• 238000005534 hematocrit Methods 0.000 claims description 10
• 150000003431 steroids Chemical class 0.000 claims description 10
• CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 9
• CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 9
• 235000003704 aspartic acid Nutrition 0.000 claims description 9
• OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 9
• 229960001265 ciclosporin Drugs 0.000 claims description 9
• 210000004185 liver Anatomy 0.000 claims description 9
• 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 9
• 229930105110 Cyclosporin A Natural products 0.000 claims description 8
• 208000010412 Glaucoma Diseases 0.000 claims description 8
• FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 claims description 8
• 108091008874 T cell receptors Proteins 0.000 claims description 8
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 8
• 239000003242 anti bacterial agent Substances 0.000 claims description 8
• 229940088710 antibiotic agent Drugs 0.000 claims description 8
• 210000001736 capillary Anatomy 0.000 claims description 8
• 230000000913 erythropoietic effect Effects 0.000 claims description 8
• 229960004584 methylprednisolone Drugs 0.000 claims description 8
• 102000039446 nucleic acids Human genes 0.000 claims description 8
• 108020004707 nucleic acids Proteins 0.000 claims description 8
• 150000007523 nucleic acids Chemical class 0.000 claims description 8
• 150000003839 salts Chemical class 0.000 claims description 8
• 208000018737 Parkinson disease Diseases 0.000 claims description 7
• 150000001412 amines Chemical class 0.000 claims description 7
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 7
• 239000003443 antiviral agent Substances 0.000 claims description 7
• 229960001334 corticosteroids Drugs 0.000 claims description 7
• 229960004397 cyclophosphamide Drugs 0.000 claims description 7
• 230000007423 decrease Effects 0.000 claims description 7
• 206010014599 encephalitis Diseases 0.000 claims description 7
• 210000005168 endometrial cell Anatomy 0.000 claims description 7
• 229940015043 glyoxal Drugs 0.000 claims description 7
• PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 7
• 210000004498 neuroglial cell Anatomy 0.000 claims description 7
• 206010012289 Dementia Diseases 0.000 claims description 6
• 102000005744 Glycoside Hydrolases Human genes 0.000 claims description 6
• 108010031186 Glycoside Hydrolases Proteins 0.000 claims description 6
• FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 6
• 125000000217 alkyl group Chemical group 0.000 claims description 6
• 230000006907 apoptotic process Effects 0.000 claims description 6
• 125000003118 aryl group Chemical group 0.000 claims description 6
• 229960002170 azathioprine Drugs 0.000 claims description 6
• LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims description 6
• 229960003067 cystine Drugs 0.000 claims description 6
• 230000002357 endometrial effect Effects 0.000 claims description 6
• VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims description 6
• 229960000681 leflunomide Drugs 0.000 claims description 6
• 229960000485 methotrexate Drugs 0.000 claims description 6
• ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 claims description 6
• 229940075993 receptor modulator Drugs 0.000 claims description 6
• 208000032253 retinal ischemia Diseases 0.000 claims description 6
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
• 208000020431 spinal cord injury Diseases 0.000 claims description 6
• 210000000130 stem cell Anatomy 0.000 claims description 6
• LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims description 5
• NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical group OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 claims description 5
• 208000030507 AIDS Diseases 0.000 claims description 5
• 208000024827 Alzheimer disease Diseases 0.000 claims description 5
• 201000006474 Brain Ischemia Diseases 0.000 claims description 5
• 206010006458 Bronchitis chronic Diseases 0.000 claims description 5
• 206010008120 Cerebral ischaemia Diseases 0.000 claims description 5
• 201000009906 Meningitis Diseases 0.000 claims description 5
• 206010031252 Osteomyelitis Diseases 0.000 claims description 5
• 206010033645 Pancreatitis Diseases 0.000 claims description 5
• 206010047139 Vasoconstriction Diseases 0.000 claims description 5
• 229940125388 beta agonist Drugs 0.000 claims description 5
• 206010006451 bronchitis Diseases 0.000 claims description 5
• 206010008118 cerebral infarction Diseases 0.000 claims description 5
• 208000007451 chronic bronchitis Diseases 0.000 claims description 5
• 239000003862 glucocorticoid Substances 0.000 claims description 5
• 239000010931 gold Substances 0.000 claims description 5
• 229910052737 gold Inorganic materials 0.000 claims description 5
• 230000037417 hyperactivation Effects 0.000 claims description 5
• 208000002780 macular degeneration Diseases 0.000 claims description 5
• DYKFCLLONBREIL-KVUCHLLUSA-N minocycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=CC(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O DYKFCLLONBREIL-KVUCHLLUSA-N 0.000 claims description 5
• 229960004023 minocycline Drugs 0.000 claims description 5
• 208000010125 myocardial infarction Diseases 0.000 claims description 5
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 5
• 229960001639 penicillamine Drugs 0.000 claims description 5
• 210000001013 sinoatrial node Anatomy 0.000 claims description 5
• NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 5
• 208000009174 transverse myelitis Diseases 0.000 claims description 5
• 230000025033 vasoconstriction Effects 0.000 claims description 5
• RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 claims description 4
• 208000007848 Alcoholism Diseases 0.000 claims description 4
• 208000000044 Amnesia Diseases 0.000 claims description 4
• 208000019901 Anxiety disease Diseases 0.000 claims description 4
• 206010003805 Autism Diseases 0.000 claims description 4
• 208000020706 Autistic disease Diseases 0.000 claims description 4
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
• 208000003098 Ganglion Cysts Diseases 0.000 claims description 4
• 206010018364 Glomerulonephritis Diseases 0.000 claims description 4
• UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 4
• 208000026139 Memory disease Diseases 0.000 claims description 4
• 206010051606 Necrotising colitis Diseases 0.000 claims description 4
• 206010028885 Necrotising fasciitis Diseases 0.000 claims description 4
• 208000003435 Optic Neuritis Diseases 0.000 claims description 4
• 208000005400 Synovial Cyst Diseases 0.000 claims description 4
• 201000007930 alcohol dependence Diseases 0.000 claims description 4
• 210000000411 amacrine cell Anatomy 0.000 claims description 4
• 210000001992 atrioventricular node Anatomy 0.000 claims description 4
• 230000003115 biocidal effect Effects 0.000 claims description 4
• PHEZJEYUWHETKO-UHFFFAOYSA-N brequinar Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 claims description 4
• 229950010231 brequinar Drugs 0.000 claims description 4
• 210000004375 bundle of his Anatomy 0.000 claims description 4
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
• 230000002612 cardiopulmonary effect Effects 0.000 claims description 4
• 206010008129 cerebral palsy Diseases 0.000 claims description 4
• 239000000812 cholinergic antagonist Substances 0.000 claims description 4
• 210000003737 chromaffin cell Anatomy 0.000 claims description 4
• 201000001981 dermatomyositis Diseases 0.000 claims description 4
• 230000003325 follicular Effects 0.000 claims description 4
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 4
• BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical group NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 claims description 4
• 229960002706 gusperimus Drugs 0.000 claims description 4
• 210000003494 hepatocyte Anatomy 0.000 claims description 4
• 210000002332 leydig cell Anatomy 0.000 claims description 4
• 230000006984 memory degeneration Effects 0.000 claims description 4
• 208000023060 memory loss Diseases 0.000 claims description 4
• 210000003584 mesangial cell Anatomy 0.000 claims description 4
• 210000000327 mueller cell Anatomy 0.000 claims description 4
• 201000006417 multiple sclerosis Diseases 0.000 claims description 4
• IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 claims description 4
• 208000004995 necrotizing enterocolitis Diseases 0.000 claims description 4
• 201000007970 necrotizing fasciitis Diseases 0.000 claims description 4
• 230000004770 neurodegeneration Effects 0.000 claims description 4
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 4
• 210000003668 pericyte Anatomy 0.000 claims description 4
• 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims description 4
• 208000005987 polymyositis Diseases 0.000 claims description 4
• ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 4
• 229960002930 sirolimus Drugs 0.000 claims description 4
• QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 4
• 150000003384 small molecules Chemical class 0.000 claims description 4
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 claims description 4
• 229960001940 sulfasalazine Drugs 0.000 claims description 4
• NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 4
• VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 claims description 3
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 3
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 3
• 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 3
• 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 3
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 3
• 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
• 208000007465 Giant cell arteritis Diseases 0.000 claims description 3
• 208000036982 Spinal cord ischaemia Diseases 0.000 claims description 3
• 239000004037 angiogenesis inhibitor Substances 0.000 claims description 3
• 230000000840 anti-viral effect Effects 0.000 claims description 3
• 239000003430 antimalarial agent Substances 0.000 claims description 3
• 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 3
• 150000001718 carbodiimides Chemical class 0.000 claims description 3
• OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 claims description 3
• 125000005594 diketone group Chemical group 0.000 claims description 3
• 210000003890 endocrine cell Anatomy 0.000 claims description 3
• 208000006454 hepatitis Diseases 0.000 claims description 3
• 231100000283 hepatitis Toxicity 0.000 claims description 3
• 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 3
• 150000002484 inorganic compounds Chemical class 0.000 claims description 3
• 229910010272 inorganic material Inorganic materials 0.000 claims description 3
• RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims description 3
• 229960004866 mycophenolate mofetil Drugs 0.000 claims description 3
• 150000002894 organic compounds Chemical class 0.000 claims description 3
• 210000000608 photoreceptor cell Anatomy 0.000 claims description 3
• 210000004500 stellate cell Anatomy 0.000 claims description 3
• 208000011580 syndromic disease Diseases 0.000 claims description 3
• 229940037128 systemic glucocorticoids Drugs 0.000 claims description 3
• 206010043207 temporal arteritis Diseases 0.000 claims description 3
• 206010003591 Ataxia Diseases 0.000 claims description 2
• 206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
• MQJKPEGWNLWLTK-UHFFFAOYSA-N Dapsone Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=C1 MQJKPEGWNLWLTK-UHFFFAOYSA-N 0.000 claims description 2
• 208000019022 Mood disease Diseases 0.000 claims description 2
• 230000003872 anastomosis Effects 0.000 claims description 2
• 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims description 2
• 229960000860 dapsone Drugs 0.000 claims description 2
• 210000004186 follicle cell Anatomy 0.000 claims description 2
• 210000002816 gill Anatomy 0.000 claims description 2
• 210000002064 heart cell Anatomy 0.000 claims description 2
• 210000002287 horizontal cell Anatomy 0.000 claims description 2
• 239000002955 immunomodulating agent Substances 0.000 claims description 2
• 230000000968 intestinal effect Effects 0.000 claims description 2
• 210000000663 muscle cell Anatomy 0.000 claims description 2
• 230000002107 myocardial effect Effects 0.000 claims description 2
• 210000004457 myocytus nodalis Anatomy 0.000 claims description 2
• 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
• 230000003647 oxidation Effects 0.000 claims description 2
• 238000007254 oxidation reaction Methods 0.000 claims description 2
• 230000005855 radiation Effects 0.000 claims description 2
• 210000000717 sertoli cell Anatomy 0.000 claims description 2
• NCGJACBPALRHNG-UHFFFAOYSA-M sodium;2,4,6-trinitrobenzenesulfonate Chemical compound [Na+].[O-][N+](=O)C1=CC([N+]([O-])=O)=C(S([O-])(=O)=O)C([N+]([O-])=O)=C1 NCGJACBPALRHNG-UHFFFAOYSA-M 0.000 claims description 2
• 230000001960 triggered effect Effects 0.000 claims description 2
• 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 claims 3
• 230000002947 procoagulating effect Effects 0.000 claims 3
• 150000001510 aspartic acids Chemical class 0.000 claims 2
• 229940076085 gold Drugs 0.000 claims 2
• WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 claims 1
• PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 claims 1
• 206010057430 Retinal injury Diseases 0.000 claims 1
• 230000000078 anti-malarial effect Effects 0.000 claims 1
• 208000027744 congestion Diseases 0.000 claims 1
• 230000000762 glandular Effects 0.000 claims 1
• 210000003904 glomerular cell Anatomy 0.000 claims 1
• 229950007856 mofetil Drugs 0.000 claims 1
• 239000000203 mixture Substances 0.000 abstract description 73
• 230000002708 enhancing effect Effects 0.000 abstract description 4
• 230000009885 systemic effect Effects 0.000 abstract description 4
• 230000001747 exhibiting effect Effects 0.000 abstract description 3
• 238000011284 combination treatment Methods 0.000 abstract 1
• 239000000243 solution Substances 0.000 description 50
• 241001465754 Metazoa Species 0.000 description 39
• 239000000047 product Substances 0.000 description 37
• 208000014674 injury Diseases 0.000 description 36
• 210000004556 brain Anatomy 0.000 description 33
• 150000001875 compounds Chemical class 0.000 description 30
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 25
• 102000004196 processed proteins & peptides Human genes 0.000 description 25
• 108010075944 Erythropoietin Receptors Proteins 0.000 description 23
• 230000037396 body weight Effects 0.000 description 23
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
• 241000700159 Rattus Species 0.000 description 22
• 208000027418 Wounds and injury Diseases 0.000 description 22
• 230000006870 function Effects 0.000 description 22
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 18
• 102100036509 Erythropoietin receptor Human genes 0.000 description 18
• 235000001014 amino acid Nutrition 0.000 description 18
• KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 18
• 230000000670 limiting effect Effects 0.000 description 18
• 230000010412 perfusion Effects 0.000 description 18
• 102000005962 receptors Human genes 0.000 description 18
• 108020003175 receptors Proteins 0.000 description 18
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 17
• 230000000069 prophylactic effect Effects 0.000 description 17
• 210000005166 vasculature Anatomy 0.000 description 17
• 229940024606 amino acid Drugs 0.000 description 16
• 208000035475 disorder Diseases 0.000 description 16
• 230000001681 protective effect Effects 0.000 description 16
• WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 15
• 238000000502 dialysis Methods 0.000 description 15
• 229920001184 polypeptide Polymers 0.000 description 14
• 238000001356 surgical procedure Methods 0.000 description 14
• 229940124597 therapeutic agent Drugs 0.000 description 14
• 230000008733 trauma Effects 0.000 description 14
• LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 13
• 230000001771 impaired effect Effects 0.000 description 13
• 239000011780 sodium chloride Substances 0.000 description 13
• 230000035899 viability Effects 0.000 description 13
• 241000282412 Homo Species 0.000 description 12
• 206010021143 Hypoxia Diseases 0.000 description 12
• 239000012634 fragment Substances 0.000 description 12
• 230000007954 hypoxia Effects 0.000 description 12
• 238000002054 transplantation Methods 0.000 description 12
• 241000699670 Mus sp. Species 0.000 description 11
• 150000001413 amino acids Chemical class 0.000 description 11
• 230000026045 iodination Effects 0.000 description 11
• 238000006192 iodination reaction Methods 0.000 description 11
• 210000002966 serum Anatomy 0.000 description 11
• 208000024891 symptom Diseases 0.000 description 11
• 125000003396 thiol group Chemical group [H]S* 0.000 description 11
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
• AIJULSRZWUXGPQ-UHFFFAOYSA-N Methylglyoxal Chemical compound CC(=O)C=O AIJULSRZWUXGPQ-UHFFFAOYSA-N 0.000 description 10
• 239000004480 active ingredient Substances 0.000 description 10
• 239000000872 buffer Substances 0.000 description 10
• 239000000499 gel Substances 0.000 description 10
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
• 230000003993 interaction Effects 0.000 description 10
• 210000003491 skin Anatomy 0.000 description 10
• 239000012064 sodium phosphate buffer Substances 0.000 description 10
• 230000001225 therapeutic effect Effects 0.000 description 10
• 230000000699 topical effect Effects 0.000 description 10
• 238000007792 addition Methods 0.000 description 9
• 125000003275 alpha amino acid group Chemical group 0.000 description 9
• 229960002685 biotin Drugs 0.000 description 9
• 235000020958 biotin Nutrition 0.000 description 9
• 239000011616 biotin Substances 0.000 description 9
• 230000010437 erythropoiesis Effects 0.000 description 9
• 230000014509 gene expression Effects 0.000 description 9
• 239000007788 liquid Substances 0.000 description 9
• 210000004962 mammalian cell Anatomy 0.000 description 9
• 239000000843 powder Substances 0.000 description 9
• 230000004936 stimulating effect Effects 0.000 description 9
• 206010028980 Neoplasm Diseases 0.000 description 8
• 230000009286 beneficial effect Effects 0.000 description 8
• 210000003169 central nervous system Anatomy 0.000 description 8
• 239000003153 chemical reaction reagent Substances 0.000 description 8
• 230000001684 chronic effect Effects 0.000 description 8
• 238000004132 cross linking Methods 0.000 description 8
• 125000000524 functional group Chemical group 0.000 description 8
• 238000001990 intravenous administration Methods 0.000 description 8
• 210000004165 myocardium Anatomy 0.000 description 8
• 210000000944 nerve tissue Anatomy 0.000 description 8
• 238000006722 reduction reaction Methods 0.000 description 8
• 206010010904 Convulsion Diseases 0.000 description 7
• 108010025020 Nerve Growth Factor Proteins 0.000 description 7
• 230000002411 adverse Effects 0.000 description 7
• 239000002246 antineoplastic agent Substances 0.000 description 7
• SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 7
• 230000004087 circulation Effects 0.000 description 7
• 238000003776 cleavage reaction Methods 0.000 description 7
• 230000035487 diastolic blood pressure Effects 0.000 description 7
• 230000002124 endocrine Effects 0.000 description 7
• 210000004696 endometrium Anatomy 0.000 description 7
• 210000001508 eye Anatomy 0.000 description 7
• 229940088597 hormone Drugs 0.000 description 7
• 239000005556 hormone Substances 0.000 description 7
• 208000015181 infectious disease Diseases 0.000 description 7
• 210000005240 left ventricle Anatomy 0.000 description 7
• 229910052760 oxygen Inorganic materials 0.000 description 7
• 239000001301 oxygen Substances 0.000 description 7
• 230000008092 positive effect Effects 0.000 description 7
• 238000002360 preparation method Methods 0.000 description 7
• 238000012545 processing Methods 0.000 description 7
• 238000011321 prophylaxis Methods 0.000 description 7
• 238000001959 radiotherapy Methods 0.000 description 7
• 230000009467 reduction Effects 0.000 description 7
• 210000001525 retina Anatomy 0.000 description 7
• 230000007017 scission Effects 0.000 description 7
• SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 7
• 230000000638 stimulation Effects 0.000 description 7
• 239000000126 substance Substances 0.000 description 7
• FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 6
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
• 206010002329 Aneurysm Diseases 0.000 description 6
• 239000004475 Arginine Substances 0.000 description 6
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 6
• 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 6
• 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 6
• 208000001953 Hypotension Diseases 0.000 description 6
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
• 108010006232 Neuraminidase Proteins 0.000 description 6
• 239000013543 active substance Substances 0.000 description 6
• ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
• 238000011161 development Methods 0.000 description 6
• 230000018109 developmental process Effects 0.000 description 6
• 210000003989 endothelium vascular Anatomy 0.000 description 6
• 235000013922 glutamic acid Nutrition 0.000 description 6
• 239000004220 glutamic acid Substances 0.000 description 6
• HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 6
• 102000044890 human EPO Human genes 0.000 description 6
• JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
• 238000001802 infusion Methods 0.000 description 6
• 239000002609 medium Substances 0.000 description 6
• 230000000324 neuroprotective effect Effects 0.000 description 6
• 239000002581 neurotoxin Substances 0.000 description 6
• 231100000618 neurotoxin Toxicity 0.000 description 6
• 210000000496 pancreas Anatomy 0.000 description 6
• 238000007911 parenteral administration Methods 0.000 description 6
• 230000002093 peripheral effect Effects 0.000 description 6
• 210000001428 peripheral nervous system Anatomy 0.000 description 6
• 238000004321 preservation Methods 0.000 description 6
• 238000011084 recovery Methods 0.000 description 6
• 230000001105 regulatory effect Effects 0.000 description 6
• 239000001509 sodium citrate Substances 0.000 description 6
• NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 6
• 229940014800 succinic anhydride Drugs 0.000 description 6
• 230000032258 transport Effects 0.000 description 6
• ZGCHLOWZNKRZSN-NTSWFWBYSA-N 3-deoxyglucosone Chemical compound OC[C@@H](O)[C@@H](O)CC(=O)C=O ZGCHLOWZNKRZSN-NTSWFWBYSA-N 0.000 description 5
• UHPMJDGOAZMIID-UHFFFAOYSA-N 3-deoxyglucosone Natural products OCC1OC(O)C(=O)CC1O UHPMJDGOAZMIID-UHFFFAOYSA-N 0.000 description 5
• 206010003497 Asphyxia Diseases 0.000 description 5
• 108010051696 Growth Hormone Proteins 0.000 description 5
• 208000032843 Hemorrhage Diseases 0.000 description 5
• 102000004877 Insulin Human genes 0.000 description 5
• 108090001061 Insulin Proteins 0.000 description 5
• ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 5
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
• 102000005348 Neuraminidase Human genes 0.000 description 5
• 208000005374 Poisoning Diseases 0.000 description 5
• 102100038803 Somatotropin Human genes 0.000 description 5
• 210000001744 T-lymphocyte Anatomy 0.000 description 5
• 230000021736 acetylation Effects 0.000 description 5
• 238000006640 acetylation reaction Methods 0.000 description 5
• 230000004913 activation Effects 0.000 description 5
• 210000000988 bone and bone Anatomy 0.000 description 5
• 230000021235 carbamoylation Effects 0.000 description 5
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
• 150000007942 carboxylates Chemical group 0.000 description 5
• 239000000969 carrier Substances 0.000 description 5
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 5
• 238000007385 chemical modification Methods 0.000 description 5
• 210000004978 chinese hamster ovary cell Anatomy 0.000 description 5
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 5
• 235000018417 cysteine Nutrition 0.000 description 5
• 239000002552 dosage form Substances 0.000 description 5
• 238000002474 experimental method Methods 0.000 description 5
• 230000005714 functional activity Effects 0.000 description 5
• 230000013595 glycosylation Effects 0.000 description 5
• 238000006206 glycosylation reaction Methods 0.000 description 5
• 239000000122 growth hormone Substances 0.000 description 5
• 229940125396 insulin Drugs 0.000 description 5
• 230000000302 ischemic effect Effects 0.000 description 5
• 239000003446 ligand Substances 0.000 description 5
• 230000033001 locomotion Effects 0.000 description 5
• 230000007170 pathology Effects 0.000 description 5
• 231100000572 poisoning Toxicity 0.000 description 5
• 230000000607 poisoning effect Effects 0.000 description 5
• 230000010410 reperfusion Effects 0.000 description 5
• 230000002207 retinal effect Effects 0.000 description 5
• 238000006467 substitution reaction Methods 0.000 description 5
• 230000035322 succinylation Effects 0.000 description 5
• 238000010613 succinylation reaction Methods 0.000 description 5
• 235000000346 sugar Nutrition 0.000 description 5
• 230000001629 suppression Effects 0.000 description 5
• 238000011477 surgical intervention Methods 0.000 description 5
• 239000000725 suspension Substances 0.000 description 5
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
• 235000002374 tyrosine Nutrition 0.000 description 5
• 230000002792 vascular Effects 0.000 description 5
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
• 206010002091 Anaesthesia Diseases 0.000 description 4
• BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 4
• 241000196324 Embryophyta Species 0.000 description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
• 102000003886 Glycoproteins Human genes 0.000 description 4
• 108090000288 Glycoproteins Proteins 0.000 description 4
• 206010020772 Hypertension Diseases 0.000 description 4
• QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 4
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
• 102000007072 Nerve Growth Factors Human genes 0.000 description 4
• MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
• QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 4
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
• 208000005735 Water intoxication Diseases 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 230000001154 acute effect Effects 0.000 description 4
• 125000000539 amino acid group Chemical group 0.000 description 4
• 230000037005 anaesthesia Effects 0.000 description 4
• 239000005557 antagonist Substances 0.000 description 4
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
• 238000002512 chemotherapy Methods 0.000 description 4
• ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
• 239000006071 cream Substances 0.000 description 4
• 238000012217 deletion Methods 0.000 description 4
• 230000037430 deletion Effects 0.000 description 4
• 206010012601 diabetes mellitus Diseases 0.000 description 4
• 238000009826 distribution Methods 0.000 description 4
• 238000002523 gelfiltration Methods 0.000 description 4
• 235000011187 glycerol Nutrition 0.000 description 4
• 230000036543 hypotension Effects 0.000 description 4
• 239000004615 ingredient Substances 0.000 description 4
• 238000003780 insertion Methods 0.000 description 4
• 230000037431 insertion Effects 0.000 description 4
• 230000002503 metabolic effect Effects 0.000 description 4
• 244000005700 microbiome Species 0.000 description 4
• 210000003205 muscle Anatomy 0.000 description 4
• 239000003900 neurotrophic factor Substances 0.000 description 4
• 238000006396 nitration reaction Methods 0.000 description 4
• 239000008363 phosphate buffer Substances 0.000 description 4
• 239000002504 physiological saline solution Substances 0.000 description 4
• 239000013612 plasmid Substances 0.000 description 4
• 230000002265 prevention Effects 0.000 description 4
• 230000035755 proliferation Effects 0.000 description 4
• 230000017854 proteolysis Effects 0.000 description 4
• 230000002685 pulmonary effect Effects 0.000 description 4
• 230000002441 reversible effect Effects 0.000 description 4
• 239000002904 solvent Substances 0.000 description 4
• 241000894007 species Species 0.000 description 4
• 210000000278 spinal cord Anatomy 0.000 description 4
• 239000000829 suppository Substances 0.000 description 4
• 239000003826 tablet Substances 0.000 description 4
• 239000003053 toxin Substances 0.000 description 4
• 231100000765 toxin Toxicity 0.000 description 4
• 108700012359 toxins Proteins 0.000 description 4
• 230000031998 transcytosis Effects 0.000 description 4
• 238000012546 transfer Methods 0.000 description 4
• 102000003390 tumor necrosis factor Human genes 0.000 description 4
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
• 241000894006 Bacteria Species 0.000 description 3
• 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 3
• 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 description 3
• 102100031614 Ciliary neurotrophic factor Human genes 0.000 description 3
• 208000028698 Cognitive impairment Diseases 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 3
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 3
• 208000010496 Heart Arrest Diseases 0.000 description 3
• 241000238631 Hexapoda Species 0.000 description 3
• 208000013016 Hypoglycemia Diseases 0.000 description 3
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
• 102000000589 Interleukin-1 Human genes 0.000 description 3
• 108010002352 Interleukin-1 Proteins 0.000 description 3
• 102000000588 Interleukin-2 Human genes 0.000 description 3
• 108010002350 Interleukin-2 Proteins 0.000 description 3
• 102000000646 Interleukin-3 Human genes 0.000 description 3
• 108010002386 Interleukin-3 Proteins 0.000 description 3
• 102000004889 Interleukin-6 Human genes 0.000 description 3
• 108090001005 Interleukin-6 Proteins 0.000 description 3
• VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 3
• XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
• 102000015336 Nerve Growth Factor Human genes 0.000 description 3
• 208000012902 Nervous system disease Diseases 0.000 description 3
• 208000025966 Neurological disease Diseases 0.000 description 3
• DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
• 206010038848 Retinal detachment Diseases 0.000 description 3
• 101710165315 Sialidase A Proteins 0.000 description 3
• 229920002472 Starch Polymers 0.000 description 3
• 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 3
• 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 3
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
• 230000009471 action Effects 0.000 description 3
• 150000001299 aldehydes Chemical class 0.000 description 3
• 125000003545 alkoxy group Chemical group 0.000 description 3
• 239000003708 ampul Substances 0.000 description 3
• 238000002266 amputation Methods 0.000 description 3
• 238000004458 analytical method Methods 0.000 description 3
• 238000010171 animal model Methods 0.000 description 3
• 230000036506 anxiety Effects 0.000 description 3
• 239000007864 aqueous solution Substances 0.000 description 3
• 208000006673 asthma Diseases 0.000 description 3
• 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
• 230000001588 bifunctional effect Effects 0.000 description 3
• 230000006287 biotinylation Effects 0.000 description 3
• 238000007413 biotinylation Methods 0.000 description 3
• 210000004369 blood Anatomy 0.000 description 3
• 239000008280 blood Substances 0.000 description 3
• 239000002775 capsule Substances 0.000 description 3
• 230000003915 cell function Effects 0.000 description 3
• 230000001413 cellular effect Effects 0.000 description 3
• VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 3
• 239000000701 coagulant Substances 0.000 description 3
• 208000010877 cognitive disease Diseases 0.000 description 3
• 238000013270 controlled release Methods 0.000 description 3
• 208000029078 coronary artery disease Diseases 0.000 description 3
• 230000001054 cortical effect Effects 0.000 description 3
• 239000003431 cross linking reagent Substances 0.000 description 3
• JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 3
• 229930182912 cyclosporin Natural products 0.000 description 3
• 229940127089 cytotoxic agent Drugs 0.000 description 3
• UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 3
• 229960003957 dexamethasone Drugs 0.000 description 3
• 231100000673 dose–response relationship Toxicity 0.000 description 3
• 239000000975 dye Substances 0.000 description 3
• 230000004064 dysfunction Effects 0.000 description 3
• 206010015037 epilepsy Diseases 0.000 description 3
• 210000003743 erythrocyte Anatomy 0.000 description 3
• 125000004185 ester group Chemical group 0.000 description 3
• 229940126864 fibroblast growth factor Drugs 0.000 description 3
• 238000001914 filtration Methods 0.000 description 3
• 238000009472 formulation Methods 0.000 description 3
• 210000001035 gastrointestinal tract Anatomy 0.000 description 3
• 239000008103 glucose Substances 0.000 description 3
• 210000002175 goblet cell Anatomy 0.000 description 3
• 230000004217 heart function Effects 0.000 description 3
• 210000005260 human cell Anatomy 0.000 description 3
• 229960000890 hydrocortisone Drugs 0.000 description 3
• 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
• 230000002218 hypoglycaemic effect Effects 0.000 description 3
• 229960003444 immunosuppressant agent Drugs 0.000 description 3
• 239000003018 immunosuppressive agent Substances 0.000 description 3
• 238000011534 incubation Methods 0.000 description 3
• 230000002458 infectious effect Effects 0.000 description 3
• 230000008595 infiltration Effects 0.000 description 3
• 238000001764 infiltration Methods 0.000 description 3
• 229940076264 interleukin-3 Drugs 0.000 description 3
• 229940100601 interleukin-6 Drugs 0.000 description 3
• 210000004347 intestinal mucosa Anatomy 0.000 description 3
• 239000012948 isocyanate Substances 0.000 description 3
• 210000001865 kupffer cell Anatomy 0.000 description 3
• 239000010410 layer Substances 0.000 description 3
• 239000012280 lithium aluminium hydride Substances 0.000 description 3
• 230000007774 longterm Effects 0.000 description 3
• 239000008176 lyophilized powder Substances 0.000 description 3
• 238000012423 maintenance Methods 0.000 description 3
• 239000003550 marker Substances 0.000 description 3
• 230000007246 mechanism Effects 0.000 description 3
• 230000001404 mediated effect Effects 0.000 description 3
• 230000003340 mental effect Effects 0.000 description 3
• 230000003818 metabolic dysfunction Effects 0.000 description 3
• 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 3
• 210000000214 mouth Anatomy 0.000 description 3
• 230000035772 mutation Effects 0.000 description 3
• 229940053128 nerve growth factor Drugs 0.000 description 3
• 210000000653 nervous system Anatomy 0.000 description 3
• 229910052757 nitrogen Inorganic materials 0.000 description 3
• 239000003921 oil Substances 0.000 description 3
• 239000002674 ointment Substances 0.000 description 3
• 210000000963 osteoblast Anatomy 0.000 description 3
• 230000036961 partial effect Effects 0.000 description 3
• 230000001575 pathological effect Effects 0.000 description 3
• 230000035515 penetration Effects 0.000 description 3
• 239000000546 pharmaceutical excipient Substances 0.000 description 3
• 230000000144 pharmacologic effect Effects 0.000 description 3
• 229920005862 polyol Polymers 0.000 description 3
• 150000003077 polyols Chemical class 0.000 description 3
• GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 3
• 230000002035 prolonged effect Effects 0.000 description 3
• 230000001737 promoting effect Effects 0.000 description 3
• 239000011541 reaction mixture Substances 0.000 description 3
• 210000004994 reproductive system Anatomy 0.000 description 3
• 238000002271 resection Methods 0.000 description 3
• 230000004044 response Effects 0.000 description 3
• 230000004264 retinal detachment Effects 0.000 description 3
• 210000001116 retinal neuron Anatomy 0.000 description 3
• 230000035939 shock Effects 0.000 description 3
• 208000007056 sickle cell anemia Diseases 0.000 description 3
• 239000011734 sodium Substances 0.000 description 3
• 229910052708 sodium Inorganic materials 0.000 description 3
• 239000008107 starch Substances 0.000 description 3
• 235000019698 starch Nutrition 0.000 description 3
• 230000035882 stress Effects 0.000 description 3
• 238000007920 subcutaneous administration Methods 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 229940072041 transforming growth factor beta 2 Drugs 0.000 description 3
• GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
• LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 2
• YZHUEWSKBUJPDC-UHFFFAOYSA-N 2-(2,5-dioxopyrrolidin-1-yl)-3-(2,5-dioxopyrrol-1-yl)benzoic acid Chemical compound O=C1CCC(=O)N1C=1C(C(=O)O)=CC=CC=1N1C(=O)C=CC1=O YZHUEWSKBUJPDC-UHFFFAOYSA-N 0.000 description 2
• IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
• HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
• 201000004384 Alopecia Diseases 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• 206010002383 Angina Pectoris Diseases 0.000 description 2
• 206010058178 Aortic occlusion Diseases 0.000 description 2
• 208000023275 Autoimmune disease Diseases 0.000 description 2
• 108090001008 Avidin Proteins 0.000 description 2
• 201000004569 Blindness Diseases 0.000 description 2
• 208000014644 Brain disease Diseases 0.000 description 2
• OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
• 241000282472 Canis lupus familiaris Species 0.000 description 2
• 208000031229 Cardiomyopathies Diseases 0.000 description 2
• 208000024172 Cardiovascular disease Diseases 0.000 description 2
• 201000006306 Cor pulmonale Diseases 0.000 description 2
• 102000004420 Creatine Kinase Human genes 0.000 description 2
• 108010042126 Creatine kinase Proteins 0.000 description 2
• 239000004971 Cross linker Substances 0.000 description 2
• 241000238424 Crustacea Species 0.000 description 2
• 206010012335 Dependence Diseases 0.000 description 2
• 206010014561 Emphysema Diseases 0.000 description 2
• 208000032274 Encephalopathy Diseases 0.000 description 2
• 102000004190 Enzymes Human genes 0.000 description 2
• 108090000790 Enzymes Proteins 0.000 description 2
• ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
• 241000282326 Felis catus Species 0.000 description 2
• 208000018522 Gastrointestinal disease Diseases 0.000 description 2
• SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
• 206010019345 Heat stroke Diseases 0.000 description 2
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
• HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
• 208000021642 Muscular disease Diseases 0.000 description 2
• 201000009623 Myopathy Diseases 0.000 description 2
• JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
• 101710138657 Neurotoxin Proteins 0.000 description 2
• 244000061176 Nicotiana tabacum Species 0.000 description 2
• 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
• 241000283973 Oryctolagus cuniculus Species 0.000 description 2
• 208000002193 Pain Diseases 0.000 description 2
• 208000037658 Parkinson-dementia complex of Guam Diseases 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 2
• 206010035664 Pneumonia Diseases 0.000 description 2
• 206010037437 Pulmonary thrombosis Diseases 0.000 description 2
• 241000700157 Rattus norvegicus Species 0.000 description 2
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
• 208000017442 Retinal disease Diseases 0.000 description 2
• 208000007014 Retinitis pigmentosa Diseases 0.000 description 2
• 206010038923 Retinopathy Diseases 0.000 description 2
• 206010038926 Retinopathy hypertensive Diseases 0.000 description 2
• 206010040070 Septic Shock Diseases 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• 102100028755 Sialidase-2 Human genes 0.000 description 2
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
• NYTOUQBROMCLBJ-UHFFFAOYSA-N Tetranitromethane Chemical compound [O-][N+](=O)C([N+]([O-])=O)([N+]([O-])=O)[N+]([O-])=O NYTOUQBROMCLBJ-UHFFFAOYSA-N 0.000 description 2
• 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
• 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
• 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 2
• 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 2
• 206010053648 Vascular occlusion Diseases 0.000 description 2
• 241000700605 Viruses Species 0.000 description 2
• 210000001056 activated astrocyte Anatomy 0.000 description 2
• OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
• 210000004100 adrenal gland Anatomy 0.000 description 2
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 125000003172 aldehyde group Chemical group 0.000 description 2
• 230000009435 amidation Effects 0.000 description 2
• 238000007112 amidation reaction Methods 0.000 description 2
• 208000013968 amyotrophic lateral sclerosis-parkinsonism-dementia complex Diseases 0.000 description 2
• 208000014450 amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 Diseases 0.000 description 2
• 230000001772 anti-angiogenic effect Effects 0.000 description 2
• 229940124599 anti-inflammatory drug Drugs 0.000 description 2
• 230000000692 anti-sense effect Effects 0.000 description 2
• 210000000709 aorta Anatomy 0.000 description 2
• 206010003246 arthritis Diseases 0.000 description 2
• 230000003143 atherosclerotic effect Effects 0.000 description 2
• 230000001363 autoimmune Effects 0.000 description 2
• 239000011324 bead Substances 0.000 description 2
• 230000008901 benefit Effects 0.000 description 2
• 102000005936 beta-Galactosidase Human genes 0.000 description 2
• 108010005774 beta-Galactosidase Proteins 0.000 description 2
• 230000015572 biosynthetic process Effects 0.000 description 2
• 230000000903 blocking effect Effects 0.000 description 2
• 230000036772 blood pressure Effects 0.000 description 2
• 229960003150 bupivacaine Drugs 0.000 description 2
• JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 2
• RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 229910052791 calcium Inorganic materials 0.000 description 2
• 125000004432 carbon atom Chemical group C* 0.000 description 2
• 230000030833 cell death Effects 0.000 description 2
• 230000002490 cerebral effect Effects 0.000 description 2
• 239000003638 chemical reducing agent Substances 0.000 description 2
• 229960003920 cocaine Drugs 0.000 description 2
• 230000006835 compression Effects 0.000 description 2
• 238000007906 compression Methods 0.000 description 2
• 239000012141 concentrate Substances 0.000 description 2
• 235000008504 concentrate Nutrition 0.000 description 2
• 210000002808 connective tissue Anatomy 0.000 description 2
• 208000018631 connective tissue disease Diseases 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 238000001816 cooling Methods 0.000 description 2
• 210000004351 coronary vessel Anatomy 0.000 description 2
• XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 2
• 125000000753 cycloalkyl group Chemical group 0.000 description 2
• 230000034994 death Effects 0.000 description 2
• 238000010790 dilution Methods 0.000 description 2
• 239000012895 dilution Substances 0.000 description 2
• 239000012153 distilled water Substances 0.000 description 2
• 230000004821 effect on bone Effects 0.000 description 2
• 239000000839 emulsion Substances 0.000 description 2
• 201000002491 encephalomyelitis Diseases 0.000 description 2
• 230000008497 endothelial barrier function Effects 0.000 description 2
• 230000003511 endothelial effect Effects 0.000 description 2
• 210000002919 epithelial cell Anatomy 0.000 description 2
• 125000001033 ether group Chemical group 0.000 description 2
• 239000013604 expression vector Substances 0.000 description 2
• 239000006260 foam Substances 0.000 description 2
• 108020001507 fusion proteins Proteins 0.000 description 2
• 102000037865 fusion proteins Human genes 0.000 description 2
• 230000002496 gastric effect Effects 0.000 description 2
• 229920000159 gelatin Polymers 0.000 description 2
• 235000019322 gelatine Nutrition 0.000 description 2
• 210000004907 gland Anatomy 0.000 description 2
• 230000001434 glomerular Effects 0.000 description 2
• 229940075507 glyceryl monostearate Drugs 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 230000003394 haemopoietic effect Effects 0.000 description 2
• 210000005003 heart tissue Anatomy 0.000 description 2
• 210000002443 helper t lymphocyte Anatomy 0.000 description 2
• 229960002897 heparin Drugs 0.000 description 2
• 229920000669 heparin Polymers 0.000 description 2
• 125000001072 heteroaryl group Chemical group 0.000 description 2
• HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
• 201000001948 hypertensive retinopathy Diseases 0.000 description 2
• 208000021822 hypotensive Diseases 0.000 description 2
• 230000001077 hypotensive effect Effects 0.000 description 2
• 150000002466 imines Chemical class 0.000 description 2
• 238000007654 immersion Methods 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 230000001976 improved effect Effects 0.000 description 2
• 230000002779 inactivation Effects 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 230000028709 inflammatory response Effects 0.000 description 2
• 210000002570 interstitial cell Anatomy 0.000 description 2
• 238000001361 intraarterial administration Methods 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 239000007928 intraperitoneal injection Substances 0.000 description 2
• PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 2
• 238000005342 ion exchange Methods 0.000 description 2
• 208000023589 ischemic disease Diseases 0.000 description 2
• 210000004153 islets of langerhan Anatomy 0.000 description 2
• 208000017169 kidney disease Diseases 0.000 description 2
• 239000008101 lactose Substances 0.000 description 2
• 239000002502 liposome Substances 0.000 description 2
• 210000005229 liver cell Anatomy 0.000 description 2
• 230000003137 locomotive effect Effects 0.000 description 2
• 206010025135 lupus erythematosus Diseases 0.000 description 2
• 210000004698 lymphocyte Anatomy 0.000 description 2
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 210000004379 membrane Anatomy 0.000 description 2
• 239000012528 membrane Substances 0.000 description 2
• 208000030159 metabolic disease Diseases 0.000 description 2
• 230000004060 metabolic process Effects 0.000 description 2
• 210000003657 middle cerebral artery Anatomy 0.000 description 2
• 210000003470 mitochondria Anatomy 0.000 description 2
• 210000003928 nasal cavity Anatomy 0.000 description 2
• 210000005036 nerve Anatomy 0.000 description 2
• 230000000926 neurological effect Effects 0.000 description 2
• 230000007658 neurological function Effects 0.000 description 2
• 230000016273 neuron death Effects 0.000 description 2
• 230000007935 neutral effect Effects 0.000 description 2
• FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 2
• 210000001331 nose Anatomy 0.000 description 2
• 235000019198 oils Nutrition 0.000 description 2
• 210000003300 oropharynx Anatomy 0.000 description 2
• 210000002997 osteoclast Anatomy 0.000 description 2
• 238000004806 packaging method and process Methods 0.000 description 2
• 230000036407 pain Effects 0.000 description 2
• 239000012188 paraffin wax Substances 0.000 description 2
• 230000003071 parasitic effect Effects 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 239000006072 paste Substances 0.000 description 2
• 230000009518 penetrating injury Effects 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 230000008569 process Effects 0.000 description 2
• 230000008707 rearrangement Effects 0.000 description 2
• 238000003259 recombinant expression Methods 0.000 description 2
• 230000001172 regenerating effect Effects 0.000 description 2
• 210000002254 renal artery Anatomy 0.000 description 2
• 208000023504 respiratory system disease Diseases 0.000 description 2
• 210000001927 retinal artery Anatomy 0.000 description 2
• 230000004243 retinal function Effects 0.000 description 2
• 210000001957 retinal vein Anatomy 0.000 description 2
• YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
• 201000000306 sarcoidosis Diseases 0.000 description 2
• 230000036303 septic shock Effects 0.000 description 2
• 235000004400 serine Nutrition 0.000 description 2
• 208000019116 sleep disease Diseases 0.000 description 2
• 239000000779 smoke Substances 0.000 description 2
• 239000012279 sodium borohydride Substances 0.000 description 2
• 229910000033 sodium borohydride Inorganic materials 0.000 description 2
• 239000007787 solid Substances 0.000 description 2
• 239000007921 spray Substances 0.000 description 2
• 239000008223 sterile water Substances 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 210000002536 stromal cell Anatomy 0.000 description 2
• 239000000758 substrate Substances 0.000 description 2
• 239000006188 syrup Substances 0.000 description 2
• 235000020357 syrup Nutrition 0.000 description 2
• 125000003831 tetrazolyl group Chemical group 0.000 description 2
• 210000001578 tight junction Anatomy 0.000 description 2
• 230000000451 tissue damage Effects 0.000 description 2
• 231100000827 tissue damage Toxicity 0.000 description 2
• 210000003371 toe Anatomy 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 230000001131 transforming effect Effects 0.000 description 2
• 229940099456 transforming growth factor beta 1 Drugs 0.000 description 2
• 230000000472 traumatic effect Effects 0.000 description 2
• 210000005239 tubule Anatomy 0.000 description 2
• 230000002485 urinary effect Effects 0.000 description 2
• 208000021331 vascular occlusion disease Diseases 0.000 description 2
• 239000013598 vector Substances 0.000 description 2
• 235000015112 vegetable and seed oil Nutrition 0.000 description 2
• 239000008158 vegetable oil Substances 0.000 description 2
• 230000002861 ventricular Effects 0.000 description 2
• 239000013603 viral vector Substances 0.000 description 2
• 230000003612 virological effect Effects 0.000 description 2
• 230000004393 visual impairment Effects 0.000 description 2
• 238000005303 weighing Methods 0.000 description 2
• 238000002689 xenotransplantation Methods 0.000 description 2
• FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 1
• GKSPIZSKQWTXQG-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-[1-(pyridin-2-yldisulfanyl)ethyl]benzoate Chemical compound C=1C=C(C(=O)ON2C(CCC2=O)=O)C=CC=1C(C)SSC1=CC=CC=N1 GKSPIZSKQWTXQG-UHFFFAOYSA-N 0.000 description 1
• DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
• ZZYYVZYAZCMNPG-MLWJPKLSSA-N (2s)-6-amino-2-(1-carboxyethylamino)hexanoic acid Chemical group OC(=O)C(C)N[C@H](C(O)=O)CCCCN ZZYYVZYAZCMNPG-MLWJPKLSSA-N 0.000 description 1
• 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
• BLTRCTCTKKJRIC-UHFFFAOYSA-N 1-(cyclohexylmethyl)pyrrole-2,5-dione Chemical compound O=C1C=CC(=O)N1CC1CCCCC1 BLTRCTCTKKJRIC-UHFFFAOYSA-N 0.000 description 1
• VHYRLCJMMJQUBY-UHFFFAOYSA-N 1-[4-[4-(2,5-dioxopyrrol-1-yl)phenyl]butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCC1=CC=C(N2C(C=CC2=O)=O)C=C1 VHYRLCJMMJQUBY-UHFFFAOYSA-N 0.000 description 1
• CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
• AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
• NHJVRSWLHSJWIN-UHFFFAOYSA-M 2,4,6-trinitrobenzenesulfonate Chemical group [O-][N+](=O)C1=CC([N+]([O-])=O)=C(S([O-])(=O)=O)C([N+]([O-])=O)=C1 NHJVRSWLHSJWIN-UHFFFAOYSA-M 0.000 description 1
• MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
• KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
• SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 description 1
• LBYBJJOUISDNRJ-UHFFFAOYSA-N 4-isothiocyanatobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(N=C=S)C=C1 LBYBJJOUISDNRJ-UHFFFAOYSA-N 0.000 description 1
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
• NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical group C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
• 241001552669 Adonis annua Species 0.000 description 1
• 208000000884 Airway Obstruction Diseases 0.000 description 1
• QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
• 206010002199 Anaphylactic shock Diseases 0.000 description 1
• 102400000068 Angiostatin Human genes 0.000 description 1
• 108010079709 Angiostatins Proteins 0.000 description 1
• 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
• 108010002913 Asialoglycoproteins Proteins 0.000 description 1
• DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 208000030016 Avascular necrosis Diseases 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• 206010061688 Barotrauma Diseases 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• 206010049765 Bradyarrhythmia Diseases 0.000 description 1
• 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
• TXCIAUNLDRJGJZ-UHFFFAOYSA-N CMP-N-acetyl neuraminic acid Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OP(O)(=O)OCC1C(O)C(O)C(N2C(N=C(N)C=C2)=O)O1 TXCIAUNLDRJGJZ-UHFFFAOYSA-N 0.000 description 1
• TXCIAUNLDRJGJZ-BILDWYJOSA-N CMP-N-acetyl-beta-neuraminic acid Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@]1(C(O)=O)OP(O)(=O)OC[C@@H]1[C@@H](O)[C@@H](O)[C@H](N2C(N=C(N)C=C2)=O)O1 TXCIAUNLDRJGJZ-BILDWYJOSA-N 0.000 description 1
• 244000025254 Cannabis sativa Species 0.000 description 1
• 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
• 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
• 108090000565 Capsid Proteins Proteins 0.000 description 1
• UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
• 208000001408 Carbon monoxide poisoning Diseases 0.000 description 1
• 201000009030 Carcinoma Diseases 0.000 description 1
• 108090000426 Caspase-1 Proteins 0.000 description 1
• 102100035904 Caspase-1 Human genes 0.000 description 1
• 241000701489 Cauliflower mosaic virus Species 0.000 description 1
• 102100023321 Ceruloplasmin Human genes 0.000 description 1
• 102100039496 Choline transporter-like protein 4 Human genes 0.000 description 1
• 208000017667 Chronic Disease Diseases 0.000 description 1
• 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
• 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
• 206010010254 Concussion Diseases 0.000 description 1
• 206010011086 Coronary artery occlusion Diseases 0.000 description 1
• 241000699802 Cricetulus griseus Species 0.000 description 1
• 201000003883 Cystic fibrosis Diseases 0.000 description 1
• 206010011878 Deafness Diseases 0.000 description 1
• 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
• 206010011951 Decompression Sickness Diseases 0.000 description 1
• 208000031124 Dementia Alzheimer type Diseases 0.000 description 1
• MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
• 208000021866 Dressler syndrome Diseases 0.000 description 1
• 208000003870 Drug Overdose Diseases 0.000 description 1
• 206010013754 Drug withdrawal syndrome Diseases 0.000 description 1
• 238000002965 ELISA Methods 0.000 description 1
• 208000005189 Embolism Diseases 0.000 description 1
• 208000027534 Emotional disease Diseases 0.000 description 1
• 208000017701 Endocrine disease Diseases 0.000 description 1
• 108010079505 Endostatins Proteins 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 208000010201 Exanthema Diseases 0.000 description 1
• 208000003241 Fat Embolism Diseases 0.000 description 1
• 206010016654 Fibrosis Diseases 0.000 description 1
• 208000018478 Foetal disease Diseases 0.000 description 1
• 101150004054 GRID1 gene Proteins 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• 239000001828 Gelatine Substances 0.000 description 1
• 239000004471 Glycine Substances 0.000 description 1
• 206010056438 Growth hormone deficiency Diseases 0.000 description 1
• 208000013875 Heart injury Diseases 0.000 description 1
• 102000001554 Hemoglobins Human genes 0.000 description 1
• 108010054147 Hemoglobins Proteins 0.000 description 1
• 206010019799 Hepatitis viral Diseases 0.000 description 1
• 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
• GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 1
• 101000889282 Homo sapiens Choline transporter-like protein 4 Proteins 0.000 description 1
• 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
• 208000023105 Huntington disease Diseases 0.000 description 1
• 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
• 201000002980 Hyperparathyroidism Diseases 0.000 description 1
• 206010020751 Hypersensitivity Diseases 0.000 description 1
• 206010020850 Hyperthyroidism Diseases 0.000 description 1
• XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
• HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
• 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 1
• 208000009773 Insulin Coma Diseases 0.000 description 1
• 102000014150 Interferons Human genes 0.000 description 1
• 108010050904 Interferons Proteins 0.000 description 1
• 102000015696 Interleukins Human genes 0.000 description 1
• 108010063738 Interleukins Proteins 0.000 description 1
• 208000032382 Ischaemic stroke Diseases 0.000 description 1
• LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
• ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
• DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
• AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
• ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
• FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
• COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
• AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
• KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
• JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
• 208000006136 Leigh Disease Diseases 0.000 description 1
• ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
• NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 206010026749 Mania Diseases 0.000 description 1
• 208000027530 Meniere disease Diseases 0.000 description 1
• 208000029725 Metabolic bone disease Diseases 0.000 description 1
• 102000003792 Metallothionein Human genes 0.000 description 1
• 108090000157 Metallothionein Proteins 0.000 description 1
• 238000012347 Morris Water Maze Methods 0.000 description 1
• 241001529936 Murinae Species 0.000 description 1
• 241000699666 Mus <mouse, genus> Species 0.000 description 1
• 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
• 208000009525 Myocarditis Diseases 0.000 description 1
• 206010068871 Myotonic dystrophy Diseases 0.000 description 1
• OQVOZFPJUCUPLW-LURJTMIESA-N N-(1-Carboxymethyl)-L-lysine Chemical group NCCCC[C@@H](C(O)=O)NCC(O)=O OQVOZFPJUCUPLW-LURJTMIESA-N 0.000 description 1
• GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
• 206010029164 Nephrotic syndrome Diseases 0.000 description 1
• 206010029240 Neuritis Diseases 0.000 description 1
• 206010029350 Neurotoxicity Diseases 0.000 description 1
• 206010057852 Nicotine dependence Diseases 0.000 description 1
• 102000005823 Nucleotide-sugar transporter Human genes 0.000 description 1
• CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
• 206010030113 Oedema Diseases 0.000 description 1
• 240000007594 Oryza sativa Species 0.000 description 1
• 235000007164 Oryza sativa Nutrition 0.000 description 1
• 206010031264 Osteonecrosis Diseases 0.000 description 1
• 206010049088 Osteopenia Diseases 0.000 description 1
• 206010033296 Overdoses Diseases 0.000 description 1
• 229930040373 Paraformaldehyde Natural products 0.000 description 1
• 206010033799 Paralysis Diseases 0.000 description 1
• 235000019483 Peanut oil Nutrition 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
• 206010035742 Pneumonitis Diseases 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 229920000153 Povidone-iodine Polymers 0.000 description 1
• 208000024777 Prion disease Diseases 0.000 description 1
• ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 208000028017 Psychotic disease Diseases 0.000 description 1
• 208000010378 Pulmonary Embolism Diseases 0.000 description 1
• 206010037549 Purpura Diseases 0.000 description 1
• 241001672981 Purpura Species 0.000 description 1
• 206010037742 Rabies Diseases 0.000 description 1
• 208000033626 Renal failure acute Diseases 0.000 description 1
• 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
• 108010039491 Ricin Proteins 0.000 description 1
• 102220469221 S-adenosyl-L-methionine-dependent tRNA 4-demethylwyosine synthase TYW1B_E18A_mutation Human genes 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 206010059594 Secondary hypogonadism Diseases 0.000 description 1
• 206010039966 Senile dementia Diseases 0.000 description 1
• 206010040576 Shock hypoglycaemic Diseases 0.000 description 1
• 108050000175 Sialidase-2 Proteins 0.000 description 1
• 102000003838 Sialyltransferases Human genes 0.000 description 1
• 108090000141 Sialyltransferases Proteins 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• 206010041549 Spinal cord compression Diseases 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 208000006011 Stroke Diseases 0.000 description 1
• 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
• 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
• 208000002667 Subdural Hematoma Diseases 0.000 description 1
• 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
• 239000004473 Threonine Substances 0.000 description 1
• 108010022394 Threonine synthase Proteins 0.000 description 1
• 102000000591 Tight Junction Proteins Human genes 0.000 description 1
• 108010002321 Tight Junction Proteins Proteins 0.000 description 1
• 208000025569 Tobacco Use disease Diseases 0.000 description 1
• 241000723873 Tobacco mosaic virus Species 0.000 description 1
• 206010044221 Toxic encephalopathy Diseases 0.000 description 1
• 208000030886 Traumatic Brain injury Diseases 0.000 description 1
• 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
• 206010068268 Tumour compression Diseases 0.000 description 1
• 208000025865 Ulcer Diseases 0.000 description 1
• KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
• 206010047571 Visual impairment Diseases 0.000 description 1
• 229930003427 Vitamin E Natural products 0.000 description 1
• 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
• 206010047642 Vitiligo Diseases 0.000 description 1
• 208000018839 Wilson disease Diseases 0.000 description 1
• OGQICQVSFDPSEI-UHFFFAOYSA-N Zorac Chemical compound N1=CC(C(=O)OCC)=CC=C1C#CC1=CC=C(SCCC2(C)C)C2=C1 OGQICQVSFDPSEI-UHFFFAOYSA-N 0.000 description 1
• 230000002159 abnormal effect Effects 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 238000010521 absorption reaction Methods 0.000 description 1
• 238000009825 accumulation Methods 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 229960001138 acetylsalicylic acid Drugs 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 210000001642 activated microglia Anatomy 0.000 description 1
• 229960005305 adenosine Drugs 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 230000007000 age related cognitive decline Effects 0.000 description 1
• 235000004279 alanine Nutrition 0.000 description 1
• 150000001298 alcohols Chemical class 0.000 description 1
• 125000001931 aliphatic group Chemical group 0.000 description 1
• 230000000172 allergic effect Effects 0.000 description 1
• 231100000360 alopecia Toxicity 0.000 description 1
• 150000001408 amides Chemical class 0.000 description 1
• 208000003455 anaphylaxis Diseases 0.000 description 1
• 206010068168 androgenetic alopecia Diseases 0.000 description 1
• 210000002159 anterior chamber Anatomy 0.000 description 1
• 230000001078 anti-cholinergic effect Effects 0.000 description 1
• 229940121375 antifungal agent Drugs 0.000 description 1
• 239000003429 antifungal agent Substances 0.000 description 1
• 239000000427 antigen Substances 0.000 description 1
• 108091007433 antigens Proteins 0.000 description 1
• 102000036639 antigens Human genes 0.000 description 1
• 229940033495 antimalarials Drugs 0.000 description 1
• 239000003963 antioxidant agent Substances 0.000 description 1
• 235000006708 antioxidants Nutrition 0.000 description 1
• 229940121357 antivirals Drugs 0.000 description 1
• 210000000702 aorta abdominal Anatomy 0.000 description 1
• 239000012062 aqueous buffer Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 230000006793 arrhythmia Effects 0.000 description 1
• 206010003119 arrhythmia Diseases 0.000 description 1
• 208000021328 arterial occlusion Diseases 0.000 description 1
• 210000001367 artery Anatomy 0.000 description 1
• 235000009582 asparagine Nutrition 0.000 description 1
• 229960001230 asparagine Drugs 0.000 description 1
• FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 208000010668 atopic eczema Diseases 0.000 description 1
• 230000037424 autonomic function Effects 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 230000001580 bacterial effect Effects 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 210000002469 basement membrane Anatomy 0.000 description 1
• 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
• 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000004071 biological effect Effects 0.000 description 1
• 125000004057 biotinyl group Chemical group [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
• 208000034158 bleeding Diseases 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 230000017531 blood circulation Effects 0.000 description 1
• 230000023555 blood coagulation Effects 0.000 description 1
• 210000004204 blood vessel Anatomy 0.000 description 1
• 238000007664 blowing Methods 0.000 description 1
• 210000002449 bone cell Anatomy 0.000 description 1
• 208000006218 bradycardia Diseases 0.000 description 1
• 230000007177 brain activity Effects 0.000 description 1
• 210000004781 brain capillary Anatomy 0.000 description 1
• 210000004958 brain cell Anatomy 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 229960001948 caffeine Drugs 0.000 description 1
• VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
• LWQQLNNNIPYSNX-UROSTWAQSA-N calcipotriol Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1 LWQQLNNNIPYSNX-UROSTWAQSA-N 0.000 description 1
• 229960002882 calcipotriol Drugs 0.000 description 1
• 229940112129 campath Drugs 0.000 description 1
• 210000001043 capillary endothelial cell Anatomy 0.000 description 1
• 108700001003 carbamylated erythropoietin Proteins 0.000 description 1
• 229910002091 carbon monoxide Inorganic materials 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 125000002843 carboxylic acid group Chemical group 0.000 description 1
• 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 210000001326 carotid sinus Anatomy 0.000 description 1
• 230000015556 catabolic process Effects 0.000 description 1
• MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
• 229960001139 cefazolin Drugs 0.000 description 1
• 230000007248 cellular mechanism Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 201000008191 cerebritis Diseases 0.000 description 1
• 230000008859 change Effects 0.000 description 1
• 210000000349 chromosome Anatomy 0.000 description 1
• 230000007882 cirrhosis Effects 0.000 description 1
• 208000019425 cirrhosis of liver Diseases 0.000 description 1
• 239000011280 coal tar Substances 0.000 description 1
• 230000001149 cognitive effect Effects 0.000 description 1
• 230000000052 comparative effect Effects 0.000 description 1
• 230000009514 concussion Effects 0.000 description 1
• 230000021615 conjugation Effects 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
• 125000002243 cyclohexanonyl group Chemical group *C1(*)C(=O)C(*)(*)C(*)(*)C(*)(*)C1(*)* 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 210000003674 cytoplasmic vesicle Anatomy 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 230000003247 decreasing effect Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 238000006731 degradation reaction Methods 0.000 description 1
• 229940000033 dermatological agent Drugs 0.000 description 1
• 239000003241 dermatological agent Substances 0.000 description 1
• 238000010612 desalination reaction Methods 0.000 description 1
• NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
• 229960004281 desmopressin Drugs 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 229960002069 diamorphine Drugs 0.000 description 1
• 150000001990 dicarboxylic acid derivatives Chemical class 0.000 description 1
• 229960001259 diclofenac Drugs 0.000 description 1
• DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
• 102000004419 dihydrofolate reductase Human genes 0.000 description 1
• 239000003085 diluting agent Substances 0.000 description 1
• ZWIBGKZDAWNIFC-UHFFFAOYSA-N disuccinimidyl suberate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCCC(=O)ON1C(=O)CCC1=O ZWIBGKZDAWNIFC-UHFFFAOYSA-N 0.000 description 1
• 125000002228 disulfide group Chemical group 0.000 description 1
• 150000002019 disulfides Chemical class 0.000 description 1
• VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
• 230000009189 diving Effects 0.000 description 1
• 231100000725 drug overdose Toxicity 0.000 description 1
• 208000024732 dysthymic disease Diseases 0.000 description 1
• 208000002296 eclampsia Diseases 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 229920001971 elastomer Polymers 0.000 description 1
• 238000001493 electron microscopy Methods 0.000 description 1
• 239000012039 electrophile Substances 0.000 description 1
• 238000002571 electroretinography Methods 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 230000003073 embolic effect Effects 0.000 description 1
• 239000003974 emollient agent Substances 0.000 description 1
• 230000004970 emotional disturbance Effects 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 210000000750 endocrine system Anatomy 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 239000003623 enhancer Substances 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 230000009144 enzymatic modification Effects 0.000 description 1
• 210000002615 epidermis Anatomy 0.000 description 1
• 229960003276 erythromycin Drugs 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
• 201000005884 exanthem Diseases 0.000 description 1
• 230000004204 exocrine pancreatic function Effects 0.000 description 1
• 231100000573 exposure to toxins Toxicity 0.000 description 1
• 238000000605 extraction Methods 0.000 description 1
• 210000003414 extremity Anatomy 0.000 description 1
• 208000030533 eye disease Diseases 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 210000003195 fascia Anatomy 0.000 description 1
• 239000003925 fat Substances 0.000 description 1
• 239000000835 fiber Substances 0.000 description 1
• 235000013312 flour Nutrition 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 235000013305 food Nutrition 0.000 description 1
• 210000002683 foot Anatomy 0.000 description 1
• 210000005153 frontal cortex Anatomy 0.000 description 1
• BFSYFTQDGRDJNV-AYHFEMFVSA-N fructosyllysine Chemical compound OC(=O)[C@@H](N)CCCCNCC(=O)[C@@H](O)[C@H](O)[C@H](O)CO BFSYFTQDGRDJNV-AYHFEMFVSA-N 0.000 description 1
• 230000009760 functional impairment Effects 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 229930182830 galactose Natural products 0.000 description 1
• WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
• 238000001502 gel electrophoresis Methods 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000002518 glial effect Effects 0.000 description 1
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
• 235000004554 glutamine Nutrition 0.000 description 1
• RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
• 229940074045 glyceryl distearate Drugs 0.000 description 1
• 125000003147 glycosyl group Chemical group 0.000 description 1
• 210000002288 golgi apparatus Anatomy 0.000 description 1
• 244000144993 groups of animals Species 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 125000004997 halocarbonyl group Chemical group 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 230000010370 hearing loss Effects 0.000 description 1
• 231100000888 hearing loss Toxicity 0.000 description 1
• 208000016354 hearing loss disease Diseases 0.000 description 1
• 208000019622 heart disease Diseases 0.000 description 1
• 210000003709 heart valve Anatomy 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• 125000000623 heterocyclic group Chemical group 0.000 description 1
• 239000008241 heterogeneous mixture Substances 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 201000008298 histiocytosis Diseases 0.000 description 1
• 230000006801 homologous recombination Effects 0.000 description 1
• 238000002744 homologous recombination Methods 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
• 229960004171 hydroxychloroquine Drugs 0.000 description 1
• 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
• 201000008980 hyperinsulinism Diseases 0.000 description 1
• 230000002727 hyperosmolar Effects 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 201000003368 hypogonadotropic hypogonadism Diseases 0.000 description 1
• 230000000642 iatrogenic effect Effects 0.000 description 1
• 229960001680 ibuprofen Drugs 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 210000000987 immune system Anatomy 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 229940127121 immunoconjugate Drugs 0.000 description 1
• 238000000760 immunoelectrophoresis Methods 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 238000002991 immunohistochemical analysis Methods 0.000 description 1
• 238000011532 immunohistochemical staining Methods 0.000 description 1
• 239000002596 immunotoxin Substances 0.000 description 1
• 201000001881 impotence Diseases 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 208000000509 infertility Diseases 0.000 description 1
• 230000036512 infertility Effects 0.000 description 1
• 231100000535 infertility Toxicity 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 239000003112 inhibitor Substances 0.000 description 1
• 206010022498 insulinoma Diseases 0.000 description 1
• 229940079322 interferon Drugs 0.000 description 1
• 239000000543 intermediate Substances 0.000 description 1
• 208000036971 interstitial lung disease 2 Diseases 0.000 description 1
• 238000007912 intraperitoneal administration Methods 0.000 description 1
• 238000010253 intravenous injection Methods 0.000 description 1
• 239000011630 iodine Substances 0.000 description 1
• 229910052740 iodine Inorganic materials 0.000 description 1
• JDNTWHVOXJZDSN-UHFFFAOYSA-N iodoacetic acid Chemical compound OC(=O)CI JDNTWHVOXJZDSN-UHFFFAOYSA-N 0.000 description 1
• 235000014413 iron hydroxide Nutrition 0.000 description 1
• NCNCGGDMXMBVIA-UHFFFAOYSA-L iron(ii) hydroxide Chemical compound [OH-].[OH-].[Fe+2] NCNCGGDMXMBVIA-UHFFFAOYSA-L 0.000 description 1
• 230000007654 ischemic lesion Effects 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
• 229960000310 isoleucine Drugs 0.000 description 1
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 238000002684 laminectomy Methods 0.000 description 1
• 201000010901 lateral sclerosis Diseases 0.000 description 1
• 239000010985 leather Substances 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 229960004194 lidocaine Drugs 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 239000003589 local anesthetic agent Substances 0.000 description 1
• 208000018769 loss of vision Diseases 0.000 description 1
• 231100000864 loss of vision Toxicity 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 210000003141 lower extremity Anatomy 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
• 239000001095 magnesium carbonate Substances 0.000 description 1
• 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
• 235000014380 magnesium carbonate Nutrition 0.000 description 1
• 239000001755 magnesium gluconate Substances 0.000 description 1
• 235000015778 magnesium gluconate Nutrition 0.000 description 1
• 229960003035 magnesium gluconate Drugs 0.000 description 1
• 235000019359 magnesium stearate Nutrition 0.000 description 1
• 229940091250 magnesium supplement Drugs 0.000 description 1
• IAKLPCRFBAZVRW-XRDLMGPZSA-L magnesium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;hydrate Chemical compound O.[Mg+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O IAKLPCRFBAZVRW-XRDLMGPZSA-L 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 208000024714 major depressive disease Diseases 0.000 description 1
• 210000001161 mammalian embryo Anatomy 0.000 description 1
• 210000003071 memory t lymphocyte Anatomy 0.000 description 1
• 230000009245 menopause Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
• BONORRGKLJBGRV-UHFFFAOYSA-N methapyrilene hydrochloride Chemical group Cl.C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CS1 BONORRGKLJBGRV-UHFFFAOYSA-N 0.000 description 1
• 229930182817 methionine Natural products 0.000 description 1
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
• HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 235000010446 mineral oil Nutrition 0.000 description 1
• 230000004898 mitochondrial function Effects 0.000 description 1
• 230000006677 mitochondrial metabolism Effects 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000001823 molecular biology technique Methods 0.000 description 1
• ZLVYMPOQNJTFSG-QMMMGPOBSA-N monoiodotyrosine Chemical compound OC(=O)[C@@H](NI)CC1=CC=C(O)C=C1 ZLVYMPOQNJTFSG-QMMMGPOBSA-N 0.000 description 1
• 230000004899 motility Effects 0.000 description 1
• 208000005264 motor neuron disease Diseases 0.000 description 1
• 239000002324 mouth wash Substances 0.000 description 1
• 210000004877 mucosa Anatomy 0.000 description 1
• 238000002703 mutagenesis Methods 0.000 description 1
• 231100000350 mutagenesis Toxicity 0.000 description 1
• 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 229940014456 mycophenolate Drugs 0.000 description 1
• HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 239000007923 nasal drop Substances 0.000 description 1
• 229940100662 nasal drops Drugs 0.000 description 1
• 239000007922 nasal spray Substances 0.000 description 1
• 230000001537 neural effect Effects 0.000 description 1
• 230000003961 neuronal insult Effects 0.000 description 1
• 231100000189 neurotoxic Toxicity 0.000 description 1
• 230000002887 neurotoxic effect Effects 0.000 description 1
• 230000007135 neurotoxicity Effects 0.000 description 1
• 231100000228 neurotoxicity Toxicity 0.000 description 1
• 230000000508 neurotrophic effect Effects 0.000 description 1
• 238000011587 new zealand white rabbit Methods 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• 231100001223 noncarcinogenic Toxicity 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 239000002773 nucleotide Substances 0.000 description 1
• 125000003729 nucleotide group Chemical group 0.000 description 1
• 108020003699 nucleotide-sugar transporter Proteins 0.000 description 1
• 230000000414 obstructive effect Effects 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 239000003883 ointment base Substances 0.000 description 1
• 229920001542 oligosaccharide Polymers 0.000 description 1
• 150000002482 oligosaccharides Chemical class 0.000 description 1
• 229940005483 opioid analgesics Drugs 0.000 description 1
• 210000001328 optic nerve Anatomy 0.000 description 1
• 230000003287 optical effect Effects 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 238000006213 oxygenation reaction Methods 0.000 description 1
• 239000003973 paint Substances 0.000 description 1
• 238000002559 palpation Methods 0.000 description 1
• 208000019906 panic disease Diseases 0.000 description 1
• FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
• 229920002866 paraformaldehyde Polymers 0.000 description 1
• 230000001314 paroxysmal effect Effects 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 239000000312 peanut oil Substances 0.000 description 1
• 229960001412 pentobarbital Drugs 0.000 description 1
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
• 108040007629 peroxidase activity proteins Proteins 0.000 description 1
• 102000013415 peroxidase activity proteins Human genes 0.000 description 1
• 235000019271 petrolatum Nutrition 0.000 description 1
• 229940124531 pharmaceutical excipient Drugs 0.000 description 1
• 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
• COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
• 229910052698 phosphorus Inorganic materials 0.000 description 1
• 239000011574 phosphorus Substances 0.000 description 1
• 230000026731 phosphorylation Effects 0.000 description 1
• 238000006366 phosphorylation reaction Methods 0.000 description 1
• 108091008695 photoreceptors Proteins 0.000 description 1
• 238000001126 phototherapy Methods 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• 238000007747 plating Methods 0.000 description 1
• 230000008488 polyadenylation Effects 0.000 description 1
• 230000002980 postoperative effect Effects 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 239000008057 potassium phosphate buffer Substances 0.000 description 1
• 159000000001 potassium salts Chemical class 0.000 description 1
• 229960001621 povidone-iodine Drugs 0.000 description 1
• 229960004618 prednisone Drugs 0.000 description 1
• XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
• MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
• 229960004919 procaine Drugs 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
• 230000009145 protein modification Effects 0.000 description 1
• 208000020016 psychiatric disease Diseases 0.000 description 1
• 229940001470 psychoactive drug Drugs 0.000 description 1
• 239000004089 psychotropic agent Substances 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
• 125000005493 quinolyl group Chemical group 0.000 description 1
• 206010037844 rash Diseases 0.000 description 1
• 239000003642 reactive oxygen metabolite Substances 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 238000010188 recombinant method Methods 0.000 description 1
• 230000008929 regeneration Effects 0.000 description 1
• 238000011069 regeneration method Methods 0.000 description 1
• 230000001850 reproductive effect Effects 0.000 description 1
• 238000011160 research Methods 0.000 description 1
• 230000000241 respiratory effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 230000033764 rhythmic process Effects 0.000 description 1
• 235000009566 rice Nutrition 0.000 description 1
• 238000011808 rodent model Methods 0.000 description 1
• 102200027484 rs63750466 Human genes 0.000 description 1
• CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
• 229960004889 salicylic acid Drugs 0.000 description 1
• 239000012266 salt solution Substances 0.000 description 1
• 208000022610 schizoaffective disease Diseases 0.000 description 1
• 201000000980 schizophrenia Diseases 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 230000004799 sedative–hypnotic effect Effects 0.000 description 1
• 239000006152 selective media Substances 0.000 description 1
• 230000035807 sensation Effects 0.000 description 1
• 238000012163 sequencing technique Methods 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• 230000019491 signal transduction Effects 0.000 description 1
• 230000008054 signal transmission Effects 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 229920000260 silastic Polymers 0.000 description 1
• 239000000741 silica gel Substances 0.000 description 1
• 229910002027 silica gel Inorganic materials 0.000 description 1
• 235000020183 skimmed milk Nutrition 0.000 description 1
• 210000004927 skin cell Anatomy 0.000 description 1
• 208000017520 skin disease Diseases 0.000 description 1
• 201000002859 sleep apnea Diseases 0.000 description 1
• 208000022925 sleep disturbance Diseases 0.000 description 1
• 150000003385 sodium Chemical class 0.000 description 1
• 235000017557 sodium bicarbonate Nutrition 0.000 description 1
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
• HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
• 239000000176 sodium gluconate Substances 0.000 description 1
• 235000012207 sodium gluconate Nutrition 0.000 description 1
• 229940005574 sodium gluconate Drugs 0.000 description 1
• 229940001584 sodium metabisulfite Drugs 0.000 description 1
• 235000010262 sodium metabisulphite Nutrition 0.000 description 1
• RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 229910000162 sodium phosphate Inorganic materials 0.000 description 1
• 239000003549 soybean oil Substances 0.000 description 1
• 235000012424 soybean oil Nutrition 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 208000005198 spinal stenosis Diseases 0.000 description 1
• 210000004988 splenocyte Anatomy 0.000 description 1
• 230000002269 spontaneous effect Effects 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 230000010473 stable expression Effects 0.000 description 1
• 238000010186 staining Methods 0.000 description 1
• 239000007858 starting material Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 239000008174 sterile solution Substances 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 239000004575 stone Substances 0.000 description 1
• 210000003699 striated muscle Anatomy 0.000 description 1
• 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 150000003871 sulfonates Chemical class 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 125000004434 sulfur atom Chemical group 0.000 description 1
• 230000009182 swimming Effects 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 238000007910 systemic administration Methods 0.000 description 1
• 238000011521 systemic chemotherapy Methods 0.000 description 1
• 229960001967 tacrolimus Drugs 0.000 description 1
• QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 229960000565 tazarotene Drugs 0.000 description 1
• 229960003604 testosterone Drugs 0.000 description 1
• 125000000335 thiazolyl group Chemical group 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
• 229960000340 thiopental sodium Drugs 0.000 description 1
• 235000008521 threonine Nutrition 0.000 description 1
• 230000017423 tissue regeneration Effects 0.000 description 1
• 239000003860 topical agent Substances 0.000 description 1
• 238000013417 toxicology model Methods 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 238000001890 transfection Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 201000008757 transient arthritis Diseases 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 230000008736 traumatic injury Effects 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 208000009999 tuberous sclerosis Diseases 0.000 description 1
• 230000036269 ulceration Effects 0.000 description 1
• 210000003954 umbilical cord Anatomy 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 241000701447 unidentified baculovirus Species 0.000 description 1
• 210000002229 urogenital system Anatomy 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 239000006216 vaginal suppository Substances 0.000 description 1
• 239000004474 valine Substances 0.000 description 1
• 235000013311 vegetables Nutrition 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 210000003135 vibrissae Anatomy 0.000 description 1
• 201000001862 viral hepatitis Diseases 0.000 description 1
• 208000029257 vision disease Diseases 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 229940088594 vitamin Drugs 0.000 description 1
• 229930003231 vitamin Natural products 0.000 description 1
• 235000013343 vitamin Nutrition 0.000 description 1
• 239000011782 vitamin Substances 0.000 description 1
• 235000019165 vitamin E Nutrition 0.000 description 1
• 229940046009 vitamin E Drugs 0.000 description 1
• 239000011709 vitamin E Substances 0.000 description 1
• 150000003722 vitamin derivatives Chemical class 0.000 description 1
• 239000001993 wax Substances 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• 239000008096 xylene Substances 0.000 description 1